309735-44-2

Usage

Type of compound

Synthetic organic compound, derivative of piperidinecarboxylic acid

Uses

Intermediate in the synthesis of pharmaceutical compounds, particularly in the production of angiotensin-converting enzyme (ACE) inhibitors, which are used in the treatment of hypertension and heart failure

Structure

1-Piperidinecarboxylic acid, 3-[(phenylamino)methyl]-, 1,1-dimethylethyl ester

Functional group

Tert-butyl ester, indicating a tert-butyl group attached to the carboxylic acid functional group

Stability

More stable and easier to handle in laboratory settings due to the presence of the tert-butyl group

Safety precautions

May be harmful if ingested or inhaled, and could be a skin and eye irritant, so it should be handled with caution.

Upstream product

• 144-55-8 sodium hydrogencarbonate 
• 118156-93-7 3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 149-73-5 trimethyl orthoformate 
• 62-53-3 aniline 

Downstream Products

• 309747-21-5 thiophene-2-carboxylic acid N-(1-Boc-piperidin-3-ylmethyl)-N-phenyl amide 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 1018480-10-8 C₁₂H₁₈N₂ 
• 309748-82-1 furan-2-carboxylic acid N-(1-Boc-piperidin-3-ylmethyl)-N-phenyl amide 
• 404589-50-0 3-[(methanesulfonyl-phenyl-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 309735-80-6 N-(1-Boc-piperidin-3-ylmethyl)-N-phenyl-propionamide 
• 360555-24-4 N-(1-Boc-piperidin-3-yl-methyl)-N-phenyl-N'-ethylurea 

Relevant academic research and scientific papers

PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.

Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps

Phenylpiperidine selective serotonin reuptake inhibitors (PSSRIs) block the function of selected multidrug efflux pumps of Staphylococcus aureus. In this study PSSRI-based piperidine derivatives were prepared, evaluated for inhibition of two multidrug res

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Antipsychotic sulfonamide-heterocycles, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.